nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2C19—Teniposide—lymphatic system cancer	0.0871	0.393	CbGbCtD
Escitalopram—CYP3A4—Cytarabine—lymphatic system cancer	0.0428	0.193	CbGbCtD
Escitalopram—CYP3A4—Teniposide—lymphatic system cancer	0.0421	0.19	CbGbCtD
Escitalopram—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0295	0.133	CbGbCtD
Escitalopram—CYP3A4—Vincristine—lymphatic system cancer	0.0203	0.0914	CbGbCtD
Escitalopram—Rash—Teniposide—lymphatic system cancer	0.000563	0.000724	CcSEcCtD
Escitalopram—Dermatitis—Teniposide—lymphatic system cancer	0.000563	0.000723	CcSEcCtD
Escitalopram—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00056	0.00072	CcSEcCtD
Escitalopram—Headache—Teniposide—lymphatic system cancer	0.00056	0.000719	CcSEcCtD
Escitalopram—Pruritus—Fludarabine—lymphatic system cancer	0.000555	0.000714	CcSEcCtD
Escitalopram—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000555	0.000713	CcSEcCtD
Escitalopram—Back pain—Mitoxantrone—lymphatic system cancer	0.000554	0.000711	CcSEcCtD
Escitalopram—Leukopenia—Carmustine—lymphatic system cancer	0.000551	0.000708	CcSEcCtD
Escitalopram—Anorexia—Bleomycin—lymphatic system cancer	0.000549	0.000705	CcSEcCtD
Escitalopram—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000544	0.0007	CcSEcCtD
Escitalopram—Anaemia—Vincristine—lymphatic system cancer	0.000543	0.000698	CcSEcCtD
Escitalopram—Agitation—Vincristine—lymphatic system cancer	0.00054	0.000694	CcSEcCtD
Escitalopram—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000539	0.000693	CcSEcCtD
Escitalopram—Polyuria—Methotrexate—lymphatic system cancer	0.000539	0.000693	CcSEcCtD
Escitalopram—Hypotension—Bleomycin—lymphatic system cancer	0.000538	0.000691	CcSEcCtD
Escitalopram—Diarrhoea—Fludarabine—lymphatic system cancer	0.000537	0.00069	CcSEcCtD
Escitalopram—Convulsion—Carmustine—lymphatic system cancer	0.000533	0.000685	CcSEcCtD
Escitalopram—Hypertension—Carmustine—lymphatic system cancer	0.000532	0.000683	CcSEcCtD
Escitalopram—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000531	0.000682	CcSEcCtD
Escitalopram—Nausea—Teniposide—lymphatic system cancer	0.000531	0.000682	CcSEcCtD
Escitalopram—Anaemia—Mitoxantrone—lymphatic system cancer	0.000529	0.00068	CcSEcCtD
Escitalopram—Vertigo—Vincristine—lymphatic system cancer	0.000528	0.000678	CcSEcCtD
Escitalopram—Hepatic failure—Methotrexate—lymphatic system cancer	0.000527	0.000677	CcSEcCtD
Escitalopram—Leukopenia—Vincristine—lymphatic system cancer	0.000526	0.000676	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000524	0.000674	CcSEcCtD
Escitalopram—Myalgia—Carmustine—lymphatic system cancer	0.000524	0.000673	CcSEcCtD
Escitalopram—Chest pain—Carmustine—lymphatic system cancer	0.000524	0.000673	CcSEcCtD
Escitalopram—Anxiety—Carmustine—lymphatic system cancer	0.000522	0.000671	CcSEcCtD
Escitalopram—Paraesthesia—Bleomycin—lymphatic system cancer	0.000517	0.000664	CcSEcCtD
Escitalopram—Malaise—Mitoxantrone—lymphatic system cancer	0.000516	0.000663	CcSEcCtD
Escitalopram—Dyspnoea—Bleomycin—lymphatic system cancer	0.000513	0.000659	CcSEcCtD
Escitalopram—Renal failure acute—Methotrexate—lymphatic system cancer	0.000513	0.000659	CcSEcCtD
Escitalopram—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000512	0.000658	CcSEcCtD
Escitalopram—Convulsion—Vincristine—lymphatic system cancer	0.000509	0.000654	CcSEcCtD
Escitalopram—Hypertension—Vincristine—lymphatic system cancer	0.000507	0.000652	CcSEcCtD
Escitalopram—Confusional state—Carmustine—lymphatic system cancer	0.000507	0.000651	CcSEcCtD
Escitalopram—Oedema—Carmustine—lymphatic system cancer	0.000502	0.000646	CcSEcCtD
Escitalopram—Decreased appetite—Bleomycin—lymphatic system cancer	0.0005	0.000643	CcSEcCtD
Escitalopram—Myalgia—Vincristine—lymphatic system cancer	0.0005	0.000643	CcSEcCtD
Escitalopram—Visual disturbance—Methotrexate—lymphatic system cancer	0.0005	0.000642	CcSEcCtD
Escitalopram—Cough—Mitoxantrone—lymphatic system cancer	0.000499	0.000642	CcSEcCtD
Escitalopram—Infection—Carmustine—lymphatic system cancer	0.000499	0.000641	CcSEcCtD
Escitalopram—Vomiting—Fludarabine—lymphatic system cancer	0.000499	0.000641	CcSEcCtD
Escitalopram—Convulsion—Mitoxantrone—lymphatic system cancer	0.000496	0.000637	CcSEcCtD
Escitalopram—Rash—Fludarabine—lymphatic system cancer	0.000495	0.000636	CcSEcCtD
Escitalopram—Dermatitis—Fludarabine—lymphatic system cancer	0.000495	0.000635	CcSEcCtD
Escitalopram—Hypertension—Mitoxantrone—lymphatic system cancer	0.000494	0.000635	CcSEcCtD
Escitalopram—Pain—Bleomycin—lymphatic system cancer	0.000492	0.000632	CcSEcCtD
Escitalopram—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000492	0.000632	CcSEcCtD
Escitalopram—Headache—Fludarabine—lymphatic system cancer	0.000492	0.000632	CcSEcCtD
Escitalopram—Tachycardia—Carmustine—lymphatic system cancer	0.00049	0.00063	CcSEcCtD
Escitalopram—Chest pain—Mitoxantrone—lymphatic system cancer	0.000487	0.000626	CcSEcCtD
Escitalopram—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000487	0.000626	CcSEcCtD
Escitalopram—Myalgia—Mitoxantrone—lymphatic system cancer	0.000487	0.000626	CcSEcCtD
Escitalopram—Anxiety—Mitoxantrone—lymphatic system cancer	0.000486	0.000624	CcSEcCtD
Escitalopram—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000483	0.000621	CcSEcCtD
Escitalopram—Lethargy—Methotrexate—lymphatic system cancer	0.000483	0.000621	CcSEcCtD
Escitalopram—Discomfort—Mitoxantrone—lymphatic system cancer	0.000481	0.000619	CcSEcCtD
Escitalopram—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00048	0.000616	CcSEcCtD
Escitalopram—Oedema—Vincristine—lymphatic system cancer	0.00048	0.000616	CcSEcCtD
Escitalopram—Anorexia—Carmustine—lymphatic system cancer	0.000479	0.000615	CcSEcCtD
Escitalopram—Infection—Vincristine—lymphatic system cancer	0.000476	0.000612	CcSEcCtD
Escitalopram—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000474	0.00061	CcSEcCtD
Escitalopram—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000474	0.000608	CcSEcCtD
Escitalopram—Confusional state—Mitoxantrone—lymphatic system cancer	0.000471	0.000605	CcSEcCtD
Escitalopram—Nervous system disorder—Vincristine—lymphatic system cancer	0.00047	0.000604	CcSEcCtD
Escitalopram—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00047	0.000603	CcSEcCtD
Escitalopram—Hypotension—Carmustine—lymphatic system cancer	0.000469	0.000603	CcSEcCtD
Escitalopram—Oedema—Mitoxantrone—lymphatic system cancer	0.000467	0.0006	CcSEcCtD
Escitalopram—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000467	0.0006	CcSEcCtD
Escitalopram—Nausea—Fludarabine—lymphatic system cancer	0.000466	0.000599	CcSEcCtD
Escitalopram—Infection—Mitoxantrone—lymphatic system cancer	0.000464	0.000596	CcSEcCtD
Escitalopram—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000464	0.000596	CcSEcCtD
Escitalopram—Shock—Mitoxantrone—lymphatic system cancer	0.00046	0.000591	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000458	0.000588	CcSEcCtD
Escitalopram—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000457	0.000588	CcSEcCtD
Escitalopram—Urticaria—Bleomycin—lymphatic system cancer	0.000457	0.000588	CcSEcCtD
Escitalopram—Anorexia—Vincristine—lymphatic system cancer	0.000457	0.000587	CcSEcCtD
Escitalopram—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000456	0.000586	CcSEcCtD
Escitalopram—Body temperature increased—Bleomycin—lymphatic system cancer	0.000455	0.000585	CcSEcCtD
Escitalopram—Insomnia—Carmustine—lymphatic system cancer	0.000454	0.000584	CcSEcCtD
Escitalopram—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000454	0.000583	CcSEcCtD
Escitalopram—Irritability—Methotrexate—lymphatic system cancer	0.000452	0.000581	CcSEcCtD
Escitalopram—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000452	0.00058	CcSEcCtD
Escitalopram—Paraesthesia—Carmustine—lymphatic system cancer	0.000451	0.00058	CcSEcCtD
Escitalopram—Mood swings—Methotrexate—lymphatic system cancer	0.000449	0.000576	CcSEcCtD
Escitalopram—Hypotension—Vincristine—lymphatic system cancer	0.000448	0.000576	CcSEcCtD
Escitalopram—Dyspnoea—Carmustine—lymphatic system cancer	0.000448	0.000576	CcSEcCtD
Escitalopram—Somnolence—Carmustine—lymphatic system cancer	0.000447	0.000574	CcSEcCtD
Escitalopram—Anorexia—Mitoxantrone—lymphatic system cancer	0.000445	0.000572	CcSEcCtD
Escitalopram—Ataxia—Methotrexate—lymphatic system cancer	0.000445	0.000572	CcSEcCtD
Escitalopram—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000437	0.000562	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000437	0.000562	CcSEcCtD
Escitalopram—Decreased appetite—Carmustine—lymphatic system cancer	0.000437	0.000561	CcSEcCtD
Escitalopram—Hypotension—Mitoxantrone—lymphatic system cancer	0.000436	0.000561	CcSEcCtD
Escitalopram—Insomnia—Vincristine—lymphatic system cancer	0.000434	0.000557	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000434	0.000557	CcSEcCtD
Escitalopram—Paraesthesia—Vincristine—lymphatic system cancer	0.000431	0.000553	CcSEcCtD
Escitalopram—Pain—Carmustine—lymphatic system cancer	0.00043	0.000552	CcSEcCtD
Escitalopram—Constipation—Carmustine—lymphatic system cancer	0.00043	0.000552	CcSEcCtD
Escitalopram—Breast disorder—Methotrexate—lymphatic system cancer	0.000428	0.00055	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000426	0.000548	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000426	0.000547	CcSEcCtD
Escitalopram—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000424	0.000545	CcSEcCtD
Escitalopram—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000419	0.000539	CcSEcCtD
Escitalopram—Decreased appetite—Vincristine—lymphatic system cancer	0.000417	0.000536	CcSEcCtD
Escitalopram—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000416	0.000535	CcSEcCtD
Escitalopram—Somnolence—Mitoxantrone—lymphatic system cancer	0.000415	0.000534	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000414	0.000532	CcSEcCtD
Escitalopram—Feeling abnormal—Carmustine—lymphatic system cancer	0.000414	0.000532	CcSEcCtD
Escitalopram—Fatigue—Vincristine—lymphatic system cancer	0.000414	0.000531	CcSEcCtD
Escitalopram—Asthenia—Bleomycin—lymphatic system cancer	0.000413	0.000531	CcSEcCtD
Escitalopram—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000411	0.000528	CcSEcCtD
Escitalopram—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000411	0.000528	CcSEcCtD
Escitalopram—Pain—Vincristine—lymphatic system cancer	0.00041	0.000527	CcSEcCtD
Escitalopram—Constipation—Vincristine—lymphatic system cancer	0.00041	0.000527	CcSEcCtD
Escitalopram—Asthma—Methotrexate—lymphatic system cancer	0.000409	0.000526	CcSEcCtD
Escitalopram—Pruritus—Bleomycin—lymphatic system cancer	0.000407	0.000523	CcSEcCtD
Escitalopram—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000406	0.000522	CcSEcCtD
Escitalopram—Eosinophilia—Methotrexate—lymphatic system cancer	0.000405	0.000521	CcSEcCtD
Escitalopram—Fatigue—Mitoxantrone—lymphatic system cancer	0.000403	0.000517	CcSEcCtD
Escitalopram—Pancreatitis—Methotrexate—lymphatic system cancer	0.000401	0.000516	CcSEcCtD
Escitalopram—Constipation—Mitoxantrone—lymphatic system cancer	0.000399	0.000513	CcSEcCtD
Escitalopram—Pain—Mitoxantrone—lymphatic system cancer	0.000399	0.000513	CcSEcCtD
Escitalopram—Abdominal pain—Carmustine—lymphatic system cancer	0.000397	0.00051	CcSEcCtD
Escitalopram—Body temperature increased—Carmustine—lymphatic system cancer	0.000397	0.00051	CcSEcCtD
Escitalopram—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000392	0.000504	CcSEcCtD
Escitalopram—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000392	0.000504	CcSEcCtD
Escitalopram—Pancytopenia—Methotrexate—lymphatic system cancer	0.000389	0.000499	CcSEcCtD
Escitalopram—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000385	0.000495	CcSEcCtD
Escitalopram—Dysuria—Methotrexate—lymphatic system cancer	0.000383	0.000492	CcSEcCtD
Escitalopram—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000382	0.000491	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00038	0.000489	CcSEcCtD
Escitalopram—Body temperature increased—Vincristine—lymphatic system cancer	0.000379	0.000487	CcSEcCtD
Escitalopram—Abdominal pain—Vincristine—lymphatic system cancer	0.000379	0.000487	CcSEcCtD
Escitalopram—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000377	0.000484	CcSEcCtD
Escitalopram—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000374	0.00048	CcSEcCtD
Escitalopram—Urticaria—Mitoxantrone—lymphatic system cancer	0.000371	0.000477	CcSEcCtD
Escitalopram—Hypersensitivity—Carmustine—lymphatic system cancer	0.00037	0.000476	CcSEcCtD
Escitalopram—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000369	0.000474	CcSEcCtD
Escitalopram—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000369	0.000474	CcSEcCtD
Escitalopram—Pneumonia—Methotrexate—lymphatic system cancer	0.000367	0.000472	CcSEcCtD
Escitalopram—Vomiting—Bleomycin—lymphatic system cancer	0.000366	0.00047	CcSEcCtD
Escitalopram—Infestation NOS—Methotrexate—lymphatic system cancer	0.000365	0.000469	CcSEcCtD
Escitalopram—Infestation—Methotrexate—lymphatic system cancer	0.000365	0.000469	CcSEcCtD
Escitalopram—Depression—Methotrexate—lymphatic system cancer	0.000364	0.000468	CcSEcCtD
Escitalopram—Rash—Bleomycin—lymphatic system cancer	0.000363	0.000466	CcSEcCtD
Escitalopram—Dermatitis—Bleomycin—lymphatic system cancer	0.000363	0.000466	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000362	0.000465	CcSEcCtD
Escitalopram—Asthenia—Carmustine—lymphatic system cancer	0.00036	0.000463	CcSEcCtD
Escitalopram—Stomatitis—Methotrexate—lymphatic system cancer	0.000356	0.000457	CcSEcCtD
Escitalopram—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000355	0.000456	CcSEcCtD
Escitalopram—Hypersensitivity—Vincristine—lymphatic system cancer	0.000353	0.000454	CcSEcCtD
Escitalopram—Sweating—Methotrexate—lymphatic system cancer	0.00035	0.00045	CcSEcCtD
Escitalopram—Haematuria—Methotrexate—lymphatic system cancer	0.000348	0.000447	CcSEcCtD
Escitalopram—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000345	0.000443	CcSEcCtD
Escitalopram—Epistaxis—Methotrexate—lymphatic system cancer	0.000344	0.000442	CcSEcCtD
Escitalopram—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000344	0.000442	CcSEcCtD
Escitalopram—Asthenia—Vincristine—lymphatic system cancer	0.000344	0.000442	CcSEcCtD
Escitalopram—Diarrhoea—Carmustine—lymphatic system cancer	0.000344	0.000442	CcSEcCtD
Escitalopram—Nausea—Bleomycin—lymphatic system cancer	0.000342	0.000439	CcSEcCtD
Escitalopram—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000341	0.000438	CcSEcCtD
Escitalopram—Asthenia—Mitoxantrone—lymphatic system cancer	0.000335	0.000431	CcSEcCtD
Escitalopram—Dizziness—Carmustine—lymphatic system cancer	0.000332	0.000427	CcSEcCtD
Escitalopram—Haemoglobin—Methotrexate—lymphatic system cancer	0.000329	0.000423	CcSEcCtD
Escitalopram—Diarrhoea—Vincristine—lymphatic system cancer	0.000328	0.000422	CcSEcCtD
Escitalopram—Hepatitis—Methotrexate—lymphatic system cancer	0.000328	0.000421	CcSEcCtD
Escitalopram—Haemorrhage—Methotrexate—lymphatic system cancer	0.000328	0.000421	CcSEcCtD
Escitalopram—Pharyngitis—Methotrexate—lymphatic system cancer	0.000325	0.000418	CcSEcCtD
Escitalopram—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000323	0.000416	CcSEcCtD
Escitalopram—Urethral disorder—Methotrexate—lymphatic system cancer	0.000321	0.000413	CcSEcCtD
Escitalopram—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00032	0.000411	CcSEcCtD
Escitalopram—Vomiting—Carmustine—lymphatic system cancer	0.000319	0.00041	CcSEcCtD
Escitalopram—Dizziness—Vincristine—lymphatic system cancer	0.000317	0.000408	CcSEcCtD
Escitalopram—Rash—Carmustine—lymphatic system cancer	0.000317	0.000407	CcSEcCtD
Escitalopram—Dermatitis—Carmustine—lymphatic system cancer	0.000317	0.000407	CcSEcCtD
Escitalopram—Visual impairment—Methotrexate—lymphatic system cancer	0.000316	0.000406	CcSEcCtD
Escitalopram—Headache—Carmustine—lymphatic system cancer	0.000315	0.000404	CcSEcCtD
Escitalopram—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00031	0.000398	CcSEcCtD
Escitalopram—Eye disorder—Methotrexate—lymphatic system cancer	0.000306	0.000393	CcSEcCtD
Escitalopram—Tinnitus—Methotrexate—lymphatic system cancer	0.000305	0.000392	CcSEcCtD
Escitalopram—Vomiting—Vincristine—lymphatic system cancer	0.000305	0.000392	CcSEcCtD
Escitalopram—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000304	0.000391	CcSEcCtD
Escitalopram—Rash—Vincristine—lymphatic system cancer	0.000302	0.000389	CcSEcCtD
Escitalopram—Dermatitis—Vincristine—lymphatic system cancer	0.000302	0.000388	CcSEcCtD
Escitalopram—Headache—Vincristine—lymphatic system cancer	0.0003	0.000386	CcSEcCtD
Escitalopram—Nausea—Carmustine—lymphatic system cancer	0.000298	0.000383	CcSEcCtD
Escitalopram—Angiopathy—Methotrexate—lymphatic system cancer	0.000297	0.000382	CcSEcCtD
Escitalopram—Vomiting—Mitoxantrone—lymphatic system cancer	0.000297	0.000382	CcSEcCtD
Escitalopram—Immune system disorder—Methotrexate—lymphatic system cancer	0.000296	0.00038	CcSEcCtD
Escitalopram—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000295	0.000379	CcSEcCtD
Escitalopram—Rash—Mitoxantrone—lymphatic system cancer	0.000295	0.000378	CcSEcCtD
Escitalopram—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000294	0.000378	CcSEcCtD
Escitalopram—Chills—Methotrexate—lymphatic system cancer	0.000294	0.000378	CcSEcCtD
Escitalopram—Headache—Mitoxantrone—lymphatic system cancer	0.000293	0.000376	CcSEcCtD
Escitalopram—Alopecia—Methotrexate—lymphatic system cancer	0.000289	0.000372	CcSEcCtD
Escitalopram—Mental disorder—Methotrexate—lymphatic system cancer	0.000287	0.000369	CcSEcCtD
Escitalopram—Erythema—Methotrexate—lymphatic system cancer	0.000285	0.000366	CcSEcCtD
Escitalopram—Malnutrition—Methotrexate—lymphatic system cancer	0.000285	0.000366	CcSEcCtD
Escitalopram—Nausea—Vincristine—lymphatic system cancer	0.000285	0.000366	CcSEcCtD
Escitalopram—Dysgeusia—Methotrexate—lymphatic system cancer	0.000279	0.000359	CcSEcCtD
Escitalopram—Nausea—Mitoxantrone—lymphatic system cancer	0.000277	0.000357	CcSEcCtD
Escitalopram—Back pain—Methotrexate—lymphatic system cancer	0.000276	0.000354	CcSEcCtD
Escitalopram—Vision blurred—Methotrexate—lymphatic system cancer	0.000269	0.000345	CcSEcCtD
Escitalopram—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000265	0.00034	CcSEcCtD
Escitalopram—Anaemia—Methotrexate—lymphatic system cancer	0.000264	0.000339	CcSEcCtD
Escitalopram—Malaise—Methotrexate—lymphatic system cancer	0.000257	0.00033	CcSEcCtD
Escitalopram—Vertigo—Methotrexate—lymphatic system cancer	0.000256	0.000329	CcSEcCtD
Escitalopram—Leukopenia—Methotrexate—lymphatic system cancer	0.000255	0.000328	CcSEcCtD
Escitalopram—Cough—Methotrexate—lymphatic system cancer	0.000249	0.00032	CcSEcCtD
Escitalopram—Convulsion—Methotrexate—lymphatic system cancer	0.000247	0.000317	CcSEcCtD
Escitalopram—Chest pain—Methotrexate—lymphatic system cancer	0.000243	0.000312	CcSEcCtD
Escitalopram—Arthralgia—Methotrexate—lymphatic system cancer	0.000243	0.000312	CcSEcCtD
Escitalopram—Myalgia—Methotrexate—lymphatic system cancer	0.000243	0.000312	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000241	0.00031	CcSEcCtD
Escitalopram—Discomfort—Methotrexate—lymphatic system cancer	0.00024	0.000308	CcSEcCtD
Escitalopram—Confusional state—Methotrexate—lymphatic system cancer	0.000235	0.000302	CcSEcCtD
Escitalopram—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000233	0.000299	CcSEcCtD
Escitalopram—Infection—Methotrexate—lymphatic system cancer	0.000231	0.000297	CcSEcCtD
Escitalopram—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000228	0.000293	CcSEcCtD
Escitalopram—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000228	0.000293	CcSEcCtD
Escitalopram—Skin disorder—Methotrexate—lymphatic system cancer	0.000226	0.00029	CcSEcCtD
Escitalopram—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000225	0.000289	CcSEcCtD
Escitalopram—Anorexia—Methotrexate—lymphatic system cancer	0.000222	0.000285	CcSEcCtD
Escitalopram—Hypotension—Methotrexate—lymphatic system cancer	0.000217	0.000279	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000212	0.000272	CcSEcCtD
Escitalopram—Insomnia—Methotrexate—lymphatic system cancer	0.00021	0.00027	CcSEcCtD
Escitalopram—Paraesthesia—Methotrexate—lymphatic system cancer	0.000209	0.000269	CcSEcCtD
Escitalopram—Dyspnoea—Methotrexate—lymphatic system cancer	0.000207	0.000267	CcSEcCtD
Escitalopram—Somnolence—Methotrexate—lymphatic system cancer	0.000207	0.000266	CcSEcCtD
Escitalopram—Dyspepsia—Methotrexate—lymphatic system cancer	0.000205	0.000263	CcSEcCtD
Escitalopram—Decreased appetite—Methotrexate—lymphatic system cancer	0.000202	0.00026	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000201	0.000258	CcSEcCtD
Escitalopram—Fatigue—Methotrexate—lymphatic system cancer	0.000201	0.000258	CcSEcCtD
Escitalopram—Pain—Methotrexate—lymphatic system cancer	0.000199	0.000256	CcSEcCtD
Escitalopram—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000192	0.000246	CcSEcCtD
Escitalopram—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00019	0.000245	CcSEcCtD
Escitalopram—Urticaria—Methotrexate—lymphatic system cancer	0.000185	0.000238	CcSEcCtD
Escitalopram—Abdominal pain—Methotrexate—lymphatic system cancer	0.000184	0.000236	CcSEcCtD
Escitalopram—Body temperature increased—Methotrexate—lymphatic system cancer	0.000184	0.000236	CcSEcCtD
Escitalopram—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000171	0.00022	CcSEcCtD
Escitalopram—Asthenia—Methotrexate—lymphatic system cancer	0.000167	0.000215	CcSEcCtD
Escitalopram—Pruritus—Methotrexate—lymphatic system cancer	0.000165	0.000212	CcSEcCtD
Escitalopram—Diarrhoea—Methotrexate—lymphatic system cancer	0.000159	0.000205	CcSEcCtD
Escitalopram—Dizziness—Methotrexate—lymphatic system cancer	0.000154	0.000198	CcSEcCtD
Escitalopram—Vomiting—Methotrexate—lymphatic system cancer	0.000148	0.00019	CcSEcCtD
Escitalopram—Rash—Methotrexate—lymphatic system cancer	0.000147	0.000189	CcSEcCtD
Escitalopram—Dermatitis—Methotrexate—lymphatic system cancer	0.000147	0.000188	CcSEcCtD
Escitalopram—Headache—Methotrexate—lymphatic system cancer	0.000146	0.000187	CcSEcCtD
Escitalopram—Nausea—Methotrexate—lymphatic system cancer	0.000138	0.000178	CcSEcCtD
